Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Lilly appears to have triumphed over Novo Nordisk in the battle for the weight-loss market. While both stocks are down from ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

Eli Lilly (NYSE:LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...